Lilly has signed a research and collaboration agreement with BioArctic to develop a potential new neurodegeneration therapy combining BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate, with BioArctic receiving a $30 million upfront payment and up to $770 million in additional milestone payments.
Antengene has entered into a collaboration with UCB valued up to $1.1 billion to develop and commercialize autoimmune therapies.
Insilico has signed a major AI‑driven drug discovery deal with Lilly valued up to $2.75 billion, including a $115 million upfront payment and tiered royalties on future sales.
Sources:
BioArctic and Lilly sign research and collaboration agreement ...
UCB signs $1.1bn to autoimmune collaboration with ...
AI Drug Discovery: The $2.75B Lilly-Insilico Deal Analysis
Eli Lilly (LLY) Teams Up With BioArctic On A New ... - Simply Wall St
Eli Lilly Strikes AI Drug Discovery Deal With InSilico Worth Up to ...
Lilly's AI commitment expands through deal with Insilico
Lilly will commercialize Insilico's AI-discovered oral drug candidates
Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm
Eli Lilly, InSilico Strike AI Drug Discovery Deal - WSJ
Lilly Doubles Down on Insilico's AI Medicines, Bets up to $2.75B